As National Co-Chair of the TARGIT U.S. Registry clinical trial and President of the TARGIT Collaborative Group, breast surgeon Dennis R. Holmes, M.D., F.A.C.S., is a world-recognized expert in targeted intraoperative radiotherapy (TARGIT) with offices in Beverly Hills, Santa Monica, Glendale, and Los Angeles, California.
TARGeted Intraoperative radioTherapy (TARGIT) is a form of breast radiation that is administered as a single treatment at the time of lumpectomy to reduce the risk of cancer recurrence. TARGIT is a type of partial breast irradiation which targets radiation to the tumor site but spares the rest of the breast and surrounding tissues the effects of radiation. TARGIT takes only 30 minutes to deliver. By comparison, traditional whole breast radiotherapy administers radiation to the whole breast, chest wall, and nearby organs, and takes 3-6 weeks to complete.
TARGIT is very convenient compared to traditional radiotherapy. TARGIT requires only a 30-minute treatment which is entirely given while the patient is asleep during lumpectomy surgery. For most patients, TARGIT completely eliminates the needs for the 3-6 week course of traditional whole breast radiation normally required after lumpectomy surgery.
Also, TARGIT reduces the overall side effects of radiation by targeting and confining the radiation dose to the part of the breast from which the cancer was removed.
Most importantly, a large international study called the TARGIT-A Trial showed TARGIT to be equally effective as traditional whole breast radiotherapy at reducing the risk of cancer recurrence after lumpectomy.
Dr. Holmes is one of the world’s leading authorities in the field, with more than a decade of experience in using this procedure. He lectures internationally on TARGIT and conducts groundbreaking research on its effects as co-chair of the United States Targeted Intraoperative Radiotherapy Steering Committee. Dr. Holmes also serves as President and Chair of the TARGIT Collaborative Group, a national organization that educates physicians and patients about breast cancer treatment advancements that reduce the burden and side effects of breast cancer surgery and radiotherapy.
If you’ve been diagnosed with breast cancer and are considering a lumpectomy, you may be eligible for TARGIT if you meet the following criteria:
TARGIT was shown to be as safe as traditional whole breast radiotherapy in a large, international study called the TARGIT-A Trial. The study showed that TARGIT was equally effective as traditional whole breast radiotherapy at preventing breast cancer recurrence in women with early-stage breast cancer.
"He treated my daughter who had stage one breast cancer. He put us at ease and calmed our fears , he was the perfect surgeon for our situation."
"He has to be one of the most incredible doctor that I've been blessed to have on my survival team. He's saved my life! I'm a proud 28 yr B C survivor."
"Dr. Holmes is kind, professional, and has a lot of patience answering every question you might have."
"Great and SMART staff. Great place with ZERO infection rate. I was back to work after surgery way sooner then expected! Awesome place great center."
“Thank you so much for being caring and patient with me during this hard transition. I really appreciate your professionalism and dedication.”
“God Bless you, your mind, and your hands, so you may continue to help all women with breast cancer! We thank you for everything that you have done!"
"This week I celebrated my 55th birthday. I cannot be thankful enough for your help in giving me another chance to enjoy waking up each day."